DiaSorin (DSRLF) Set to Announce Quarterly Earnings on Thursday

DiaSorin (OTCMKTS:DSRLF) is projected to release its resultson Thursday, November 5th. Analysts expect the company to announce earnings of $2.46 per share and revenue of $340.73 million for the quarter.

DiaSorin Price Performance

Shares of DSRLF opened at $92.00 on Tuesday. The firm has a fifty day moving average price of $86.60 and a 200-day moving average price of $79.66. DiaSorin has a 12-month low of $66.50 and a 12-month high of $92.00.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on DSRLF shares. UBS Group lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, August 12th. BNP Paribas Exane downgraded shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Zacks Research raised shares of DiaSorin from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of DiaSorin in a research note on Tuesday, August 4th. Two equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, DiaSorin presently has a consensus rating of “Strong Sell”.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italian company specializing in in vitro diagnostics, with a focus on immunodiagnostics and molecular diagnostics. Its products are used by hospitals, clinical laboratories and healthcare providers to support the detection, diagnosis and monitoring of a range of diseases and medical conditions.

The company’s portfolio includes automated immunoassay systems, reagents and diagnostic tests marketed under the LIAISON family, as well as molecular diagnostic platforms and assays.